[1]朱云涛,薛刚.扶正消癥汤加减辅助SOX化疗方案在老年胃癌患者治疗中的应用[J].西部中医药,2026,39(03):156-159.[doi:10.12174/j.issn.2096-9600.2026.03.29]
 ZHU Yuntao,XUE Gang.Application of Modified Healthy Qi-reinforcing Masses-eliminating Decoction Plus Adjuvant SOX Chemotherapy in the Treatment of Elderly Patients with Gastric Cancer[J].Western Journal of Traditional Chinese Medicine,2026,39(03):156-159.[doi:10.12174/j.issn.2096-9600.2026.03.29]
点击复制

扶正消癥汤加减辅助SOX化疗方案在老年胃癌患者治疗中的应用()

《西部中医药》[ISSN:2096-9600/CN:62-1204/R]

卷:
39
期数:
2026年03期
页码:
156-159
栏目:
衷中参西
出版日期:
2026-03-15

文章信息/Info

Title:
Application of Modified Healthy Qi-reinforcing Masses-eliminating Decoction Plus Adjuvant SOX Chemotherapy in the Treatment of Elderly Patients with Gastric Cancer
作者:
朱云涛1, 薛刚2
1.江苏省人民医院溧阳分院,江苏 溧阳 213300
2.如皋市中医院,江苏 如皋 226599
Author(s):
ZHU Yuntao1, XUE Gang2
1.Liyang Branch of Jiangsu Province Hospital, Liyang 213300, China
2.Rugao Hospital of TCM, Rugao 226599, China
关键词:
胃癌奥沙利铂替吉奥扶正消癥汤肿瘤标志物免疫功能
Keywords:
gastric canceroxaliplatinS-1healthy -reinforcing masses-eliminating decoctiontumor markersimmune function
分类号:
R273
DOI:
10.12174/j.issn.2096-9600.2026.03.29
文献标志码:
B
摘要:
目的分析老年胃癌患者应用扶正消癥汤加减辅助奥沙利铂联合替吉奥(SOX方案)化疗方案的治疗效果。 方法选择老年胃癌患者76例,根据不同用药方式分为对照组与观察组各38例。对照组接受常规SOX化疗方案,观察组接受SOX化疗方案联合扶正消癥汤加减治疗。比较两组的治疗效果。 结果治疗后,两组糖类抗原125、癌胚抗原、糖类抗原199水平均较治疗前降低(P<0.05),且观察组低于对照组(P<0.05)。总有效率对照组[28.95%(11/38)]低于观察组[52.63%(20/38)](P<0.05);疾病控制率对照组[60.53%(23/38)]低于观察组[81.58%(31/38)](P<0.05)。治疗后,两组CD3+、CD4+、CD4+/CD8+、NK细胞水平均较治疗前升高(P<0.05),且观察组高于对照组(P<0.05)。治疗后,两组纳食减少、疲乏无力、大便异常、饭后腹胀积分均较治疗前降低(P<0.05),且观察组各症状积分均低于对照组(P<0.05)。 结论对老年胃癌患者应用扶正消癥汤加减辅助SOX化疗方案,能有效改善患者机体免疫功能,降低血清肿瘤标志物水平,缓解临床症状,疗效确切。
Abstract:
ObjectiveTo analyze therapeutic effects of modified healthy Qi-reinforcing masses-eliminating decoction plus adjuvant SOX chemotherapy in the treatment of elderly patients with gastric cancer. MethodsA total of 76 patients were chosen, and divided into the control group and the observation group according to different medication methods. The control group received conventional SOX chemotherapy, while the observation group was administered SOX chemotherapy in combination with modified healthy Qi-reinforcing masses-eliminating decoction. To compare therapeutic effects between the two groups. ResultsAfter the treatment, the two groups demonstrated the decreased levels of carbohydrate antigen 125 (CA125), carcinoembryonic antigen (CEA), and carbohydrate antigen 19-9 (CA19-9) compared with these before the treatment (P<0.05), and the observation group was lower than the control group (P<0.05). Total effective rate of the control group was [28.95%(11/38)], lower than [52.63%(20/38)] of the observation group (P<0.05); disease control rate (DCR) of the control group was [60.53%(23/38)], lower than [81.58%(31/38)] of the observation group (P<0.05). After the treatment, the elevated levels of CD3+, CD4+, CD4+/CD8+, NK cells were observed in the two groups than these before the treatment (P<0.05), and the observation group was higher than the control group (P<0.05). After the treatment, the reduction in the scores of anorexia, fatigue, abnormal stool and postprandial abdominal distension was more evident than that before the treatment in two groups (P<0.05), and the observation group was lower than the control group in the scores of the symptoms (P<0.05). ConclusionModified healthy Qi-reinforcing masses-eliminating decoction plus adjuvant SOX chemotherapy in the treatment of elderly patients with gastric cancer could effectively enhance the body’s immune function, lower the levels of serum tumor markers, and relieve clinical symptoms with definite clinical effects.

相似文献/References:

[1]熊墨年,唐晓玲,余炅,等.益气清毒法联合化疗治疗中晚期胃癌的临床观察[J].西部中医药,2011,24(11):35.
[2]张小仙,倪角角,陈辉.舒适护理在晚期胃癌患者中的应用[J].西部中医药,2012,25(12):105.
 ZHANG Xiao-xian,NI Jiao-jiao,CHEN Hui.Application of Comfort Care to the Patients with Gastric Cancer at Advanced Stage[J].Western Journal of Traditional Chinese Medicine,2012,25(03):105.
[3]王宏伟,程小丽,许雅清,等.苦马豆素对胃癌细胞中pten和survivin mRNA表达的影响[J].西部中医药,2015,28(12):25.
[4]胡玥,刘沈林.刘沈林教授“胃肾同治”理论探讨及其在胃癌中的应用[J].西部中医药,2015,28(10):72.
[5]朱剑梅,李世军.莲芪胶囊配合化疗治疗胃癌的临床研究[J].西部中医药,2015,28(12):91.
[6]周俭,葛信国,陈晓霞,等.益气通络方防治奥沙利铂神经毒性的临床观察[J].西部中医药,2011,24(11):25.
[7]黄菊,胡爱群,孔金芳.十全大补汤加减治疗奥沙利铂致神经毒性22例疗效观察[J].西部中医药,2012,25(09):35.
 HUANG Ju,HU Ai-qun,KONG Jin-fang.Observation on Clinical Efficacy of Modified ShiQuan DaBuTang in Treating 22 Cases of Neurotoxicity Induced by Oxaliplatin[J].Western Journal of Traditional Chinese Medicine,2012,25(03):35.
[8]李雅娟.围手术期护理对胃癌根除术患者护理质量的影响[J].西部中医药,2012,25(12):113.
 LI Ya-juan.Influence of Perioperative Care on Nursing Quality of Patients Undergoing Radical Resection of Gastric Cancer[J].Western Journal of Traditional Chinese Medicine,2012,25(03):113.
[9]刘河,刘超,杨世勇.胃癌中医证型与病灶组织中MMP-9、TIMP-2和HER-2表达的相关性分析[J].西部中医药,2017,30(02):134.
 LIU He,LIU Chao,YANG Shiyong.Correlation Analysis btween TCM Syndrome of Gastric Cancer and the Expression of MMP-9, TIMP-2 and HER-2 in Focus Tissue[J].Western Journal of Traditional Chinese Medicine,2017,30(03):134.
[10]王志新,邹玺,胡守友.中药抗胃癌的现代药理机制[J].西部中医药,2016,29(04):137.
 WANG Zhixin,ZOU Xi,HU Shouyou.Modern Pharmacological Mechanism of Herbs Fighting against Gastric Cancer[J].Western Journal of Traditional Chinese Medicine,2016,29(03):137.
[11]冯天明,王尔全,吴大平.血 汤加减联合西药对晚期胃癌患者血清CEA、CA199的影响[J].西部中医药,2021,34(08):126.[doi:10.12174/j.issn.2096-9600.2021.08.29]
 FENG Tianming,WANG Erquan,WU Daping.Effects of Modified Xuezhen Decoction Combined with Western Medicine on Serum CEA and CA199 in Patients with Advanced Gastric Cancer[J].Western Journal of Traditional Chinese Medicine,2021,34(03):126.[doi:10.12174/j.issn.2096-9600.2021.08.29]
[12]赵忆,邢磊,邢文文.康艾注射液联合SOX化疗方案治疗晚期胃癌的临床研究[J].西部中医药,2024,37(02):153.[doi:10.12174/j.issn.2096-9600.2024.02.30]
 ZHAO Yi,XING Lei,XING Wenwen.Clinical Study of Kang′ai Injection Combined with SOX Chemotherapy in the Treatment of Advanced Gastric Cancer[J].Western Journal of Traditional Chinese Medicine,2024,37(03):153.[doi:10.12174/j.issn.2096-9600.2024.02.30]

备注/Memo

备注/Memo:
江苏省中医药科技发展计划面上项目(MS2023119)。朱云涛(1988—),男,硕士学位,主治医师。研究方向:消化系统肿瘤的临床诊治。
更新日期/Last Update: 2026-03-15